IMC Chicago’s BioMarin Pharmaceuticals BMRN Stock Holding History

IMC Chicago’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.74M	Buy	30,800 +5,700	+23%	+$332K	﹤0.01%	2717
2025 Q4	$1.49M	Buy	25,100 +5,200	+26%	+$283K	﹤0.01%	2648
2025 Q3	$1.08M	Sell	19,900 -900	-4%	-$51.5K	﹤0.01%	2659
2025 Q2	$1.14M	Buy	+20,800	New	+$1.22M	﹤0.01%	2393
2023 Q3	–	Sell	-10,100	Closed	-$875K	–	1591
2023 Q2	$875K	Buy	+10,100	New	+$950K	﹤0.01%	1089
2023 Q1	–	Sell	-14,200	Closed	-$1.47M	–	1286
2022 Q4	$1.47M	Sell	14,200 -3,800	-21%	-$357K	﹤0.01%	907
2022 Q3	$1.53M	Buy	+18,000	New	+$1.6M	﹤0.01%	818
2022 Q1	–	Sell	-34,800	Closed	-$3.08M	–	1093
2021 Q4	$3.08M	Sell	34,800 -11,000	-24%	-$908K	﹤0.01%	715
2021 Q3	$3.54M	Sell	45,800 -3,400	-7%	-$268K	﹤0.01%	700
2021 Q2	$4.11M	Sell	49,200 -14,800	-23%	-$1.17M	0.01%	625
2021 Q1	$4.83M	Buy	64,000 +26,200	+69%	+$2.14M	0.01%	578
2020 Q4	$3.31M	Buy	+37,800	New	+$3M	﹤0.01%	632
2019 Q1	–	Sell	-8,700	Closed	-$741K	–	654
2018 Q4	$741K	Buy	+8,700	New	+$828K	﹤0.01%	511

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

IMC Chicago's BMRN Position: Q1 2026 in Review

IMC Chicago opened a new position in BioMarin Pharmaceuticals (BMRN) in Q1 2026: 5,600 shares worth $316K. The stake represents ﹤0.01% of the portfolio and ranks #4534 among its holdings. This is a return to the name: IMC Chicago previously reported a position in BMRN as recently as Q2 2025.

IMC Chicago first reported a position in BMRN in Q4 2018 and has held it in 5 quarters since. The position peaked at $1.82M in Q1 2021. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

IMC Chicago held 5,600 shares of BioMarin Pharmaceuticals worth $316K as of Q1 2026.
BioMarin Pharmaceuticals was a new IMC Chicago position in Q1 2026.
BioMarin Pharmaceuticals made up ﹤0.01% of IMC Chicago's portfolio in Q1 2026, its #4534 holding.
IMC Chicago first reported a position in BioMarin Pharmaceuticals in Q4 2018 and has held it in 5 quarters since.
IMC Chicago's BioMarin Pharmaceuticals position peaked at $1.82M in Q1 2021.
554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on IMC Chicago's 13F filing for Q1 2026, filed 5 May 2026.